- Home
- ANNA vs ACIU Comparison
ANNA vs ACIU Comparison
Compare ANNA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNA
- ACIU
- Stock Information
- Founded
- ANNA 2007
- ACIU 2003
- Country
- ANNA United States
- ACIU Switzerland
- Employees
- ANNA N/A
- ACIU N/A
- Industry
- ANNA
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ANNA
- ACIU Health Care
- Exchange
- ANNA NYSE
- ACIU Nasdaq
- Market Cap
- ANNA 215.9M
- ACIU 189.1M
- IPO Year
- ANNA N/A
- ACIU 2016
- Fundamental
- Price
- ANNA $5.31
- ACIU $2.12
- Analyst Decision
- ANNA
- ACIU Strong Buy
- Analyst Count
- ANNA 0
- ACIU 1
- Target Price
- ANNA N/A
- ACIU $12.00
- AVG Volume (30 Days)
- ANNA 31.9K
- ACIU 152.7K
- Earning Date
- ANNA 08-15-2025
- ACIU 08-12-2025
- Dividend Yield
- ANNA N/A
- ACIU N/A
- EPS Growth
- ANNA N/A
- ACIU N/A
- EPS
- ANNA N/A
- ACIU N/A
- Revenue
- ANNA $2,064,630.00
- ACIU $32,014,254.00
- Revenue This Year
- ANNA N/A
- ACIU N/A
- Revenue Next Year
- ANNA N/A
- ACIU $533.21
- P/E Ratio
- ANNA N/A
- ACIU N/A
- Revenue Growth
- ANNA N/A
- ACIU 91.20
- 52 Week Low
- ANNA $4.36
- ACIU $1.43
- 52 Week High
- ANNA $18.70
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- ANNA N/A
- ACIU 48.49
- Support Level
- ANNA N/A
- ACIU $2.02
- Resistance Level
- ANNA N/A
- ACIU $2.52
- Average True Range (ATR)
- ANNA 0.00
- ACIU 0.15
- MACD
- ANNA 0.00
- ACIU -0.02
- Stochastic Oscillator
- ANNA 0.00
- ACIU 23.08
About ANNA ALEANNA INC
AleAnna Inc is a developer and producer of natural gas in Italy, engaged in naturally occurring biogenic methane from conventional geological formations and carbon-negative renewable biomethane generated from farm wastes, particularly in the Po Valley of Northern Italy. It is also involved in drilling, testing, and tie-in-related activities associated with three incremental Longanesi development wells.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.